Recently, a polymorphic base in exon 13 of the BCR gene (exon b2 of the major breakpoint cluster region) has been identified in the eighth position before the junctional region of BCR-ABL cDNA. Cytosine replaces thymidine; the corresponding triplets are AAT (T allele) and AAC (C allele), respectively, both coding for asparagine. Therefore, this polymorphism has no implication in the primary structure of BCR and BCR-ABL proteins. However, since the alteration is located close to the fusion region it may have a significant influence on the annealing of PCR primers, probes for real time PCR, and antisense oligonucleotides. We have developed a RT-PCR-based screening method to easily identify polymorphic BCR and BCR-ABL alleles in CML patients and normal individuals in order to estimate their frequency. After amplification from cDNA, a melting curve of a specific fluorogenic probe mapping to the 3Ј end of BCR exon b2 and spanning the polymorphism readily discriminates between normal and polymorphic BCR and BCR-ABL alleles. This reporter probe is 3Ј labeled with fluorescein and placed next to 5Ј LC Red640-labeled anchor probes mapping to the 5Ј ends of BCR exon b3 or ABL exon a2 so that resonance energy transfer occurs when the probes are hybridized (LightCycler technology). T and C alleles were discriminated by a melting temperature difference of the reporter probe of 3.2 K. We have investigated cDNAs derived from leukocytes from seven cell lines and a total of 229 individuals: normal donors, n = 15; BCR-ABL negative chronic myeloproliferative disorders, n = 30; BCR-ABL negative acute leukemias, n = 11; b2a2 
Introduction
The two major players in the pathogenesis of CML, the protooncogene ABL on chromosome 9, and the breakpoint cluster region gene BCR on chromosome 22 cloned and sequenced in the 1980s. 1, 2 Various genomic polymorphisms have been described in context with the formation of the chimeric BCR-ABL fusion gene. However, the frequency of specific polymorphisms is still unknown. [2] [3] [4] [5] The BCR gene spans a region of 135 kb and comprises 23 exons, referred to as exons e1 to e23. Exons b1 to b5 of the major breakpoint cluster region (M-bcr) were identified as exons e12 to e16 of the BCR gene. 6, 7 The breakpoint location within BCR falls either 5Ј between exons b2 and b3 or 3Ј between exons b3 and b4. A BCR-ABL fusion gene with a b2a2 or b3a2 junction is created and transcribed. 7 Recently, a polymorphic base in exon 13 of the BCR gene (exon b2 of the major breakpoint cluster region) has been identified in the eighth position (Pos. 123692 GenBank accession No. U07000
2 ) before the junctional region of BCR-ABL cDNA. 8 Cytosine replaces thymidine; the corresponding triplets are AAT and AAC, respectively, coding both for asparagine ( Figure 1 ). Therefore, this polymorphism is silent and has no implication in the primary structure of BCR and BCR-ABL proteins. However, since the alteration is located close to the fusion region it may have a significant influence on the annealing of PCR primers, probes for real time PCR 5, [9] [10] [11] [12] [13] and therapeutic antisense oligonucleotides. 14, 15 Currently, the frequency of this polymorphism and therefore the potential impact is unknown.
To evaluate the frequency of this polymorphism and to analyze individual patients we established a novel screening method based on different melting temperatures of fluorescent-labeled oligonucleotide hybridization probes used for real time RT-PCR. Hybridization probes that bind to perfectly matched target sequences require a higher melting tempera-
Figure 1
Polymorphic site in BCR exon b2 (T123962C) according to GenBank accession No. U07000. The single base change does not have any impact on the protein sequence of BCR and BCR-ABL proteins.
ture (Tm) to dissociate compared to probes that bind to sequences with one or more mismatches. 16 
Materials and methods

Individuals and samples
A total of 229 individuals have been investigated for polymorphic BCR and/or BCR-ABL alleles. One hundred and seventythree patients had BCR-ABL positive CML at diagnosis (b2a2 BCR-ABL , n = 93; b3a2 BCR-ABL , n = 80), 56 individuals were BCR-ABL negative (healthy donors, n = 15; BCR-ABL negative chronic myeloproliferative disorders, n = 30, BCR-ABL negative acute leukemias, n = 11). In addition, cell lines K562, LAMA84 (b3a2 
Sample processing, multiplex PCR for BCR-ABL transcripts
Total leukocyte RNA was extracted from 10 to 20 ml of peripheral blood after lysis of red blood cells or from 1 to 5 × 10 7 PBS washed cells from cell lines. RNA extraction was performed by CsCl gradient centrifugation or by commercially available extraction kits. RNA was reverse transcribed using random hexamer priming and MMLV reverse transcriptase as described. 17 The type of BCR-ABL transcript was determined by multiplex PCR 18 and electrophoresis of the PCR product on an ethidium bromide stained 1.5% agarose gel and compared with K562 (b3a2 BCR-ABL ) and BV173 (b2a2 BCR-ABL ) standards.
Mutation detection using fluorescence resonance energy transfer
Fluorescence monitoring using hybridization probes is based on the concept that a fluorescence signal is generated if fluorescence resonance energy transfer (FRET) occurs between two adjacent fluorophores. 9 Even more important, genotyping using two hybridization probes is possible with a shorter 'detection probe' recognizing an adjacent sequence. The greater stability of the longer 'anchor probe' causes the 'detection probe' to melt off the template at lower temperature so that polymorphic alleles can be distinguished by the melting temperature (Tm) of the 'detection probe'. Continuous fluorescence monitoring of the reaction as the temperature is raised from annealing to denaturation results in a sharp decrease in fluorescence at the temperature at which the 'detection probe' dissociates from the template. The single base change caused by the BCR polymorphism results in a decrease of Tm of the 'detection probe' that can be distinguished with the LightCycler.
Selection of primers and design of fluorogenic probes
The following primers were used for amplification: b2a2 and b3a2 BCR-ABL, primers B2A and NA4−; 9 BCR, primers B2A and c5e−. 18 The detection probe b2-17 (5ЈCTGACCAT CAATAAGGA-F) was a 17-mer oligonucleotide, mapping to the 3Ј end of BCR exon b2 and labeled at the 3Ј end with fluorescein. The 5Ј-LightCycler Red 640-labeled anchor Leukemia probes were two 32-mer oligonucleotides that bind with a distance of three bases 3Ј to the detection probe. B3-32 maps to the 5Ј end of BCR exon b3 (5Ј LC Red640-TGAT-GAGTCTCCGGGGCTCTATGGGTTTCTGA-P), a2-32 to the 5Ј end of ABL exon a2 (5Ј LC Red640-AGCCCTT CAGCGGCCAGTAGCATCTGACTTTG-P). Therefore, detection of b3a2 BCR-ABL and BCR alleles was performed using probes b2-17 and b3-32, and detection of b2a2 BCR-ABL by using b2-17 and a2-32 ( Figure 2 ).
Real time PCR and mutation detection
PCR was performed as described. 9 After amplification was complete, a final melting curve was recorded by cooling to 40°C with 10°C/s, holding at 40°C for 1 min and then heating slowly at 0.1°C/s until 65°C. The fluorescence signal (F) was measured continuously during the temperature rise to monitor the dissociation of the fluorescein-labeled detection probe and plotted against temperature (T) to produce melting curves for each sample (F vs T). Melting curves were then converted to melting peaks by plotting the negative derivative of the fluorescence with respect to temperature against temperature (−dF/dT vs T). The actual Tm was calculated by the LightCycler software (version 3.0) (Figure 3 ). Amplification, fluorescence detection, and post-processing calculations were performed using the LightCycler (Roche Diagnostics, Mannheim, Germany).
Sequencing of amplification products
Eighteen randomly chosen amplification products of six BCR, six b2a2, and six b3a2 BCR-ABL alleles were sequenced (MWG Biotech, Ebersberg, Germany).
Quantification of BCR-ABL transcripts
In 20 b2a2
BCR-ABL positive samples (10 each with the T and C allele) BCR-ABL transcripts were quantified using b2-17 and b3-32 probes and, for comparison, using a pair of hybridization probes mapping to ABL exon 3 as described. 
Figure 2
Schematic map of the primer probe combinations for the differential detection of BCR and BCR-ABL transcripts. The pair of hybridization probes map to exons b2 and b3 for the detection of b3a2 BCR-ABL and BCR alleles and to exons b2 and a2 for the detection of b2a2 BCR-ABL alleles, respectively. The unique detection probe b2-17 was 3Ј fluorescein labeled, the two anchor probes b3-32 and a2-32 were 5Ј LC Red 640 labeled. 
Statistical analysis
The statistical significance of the difference of the frequency of polymorphism between groups was calculated using Fisher's exact test (two-sided). The results of the BCR-ABL quantification (ratio between b2/b3 and a3/a3 labeling) were compared between samples with T and C alleles, respectively, using the Mann-Whitney test. Crude odds ratios were calculated and are given within the 95% confidence intervals. Whether or not the distribution of genotypes were in HardyWeinberg equilibrium was determined by 2 analysis.
Results
Melting temperature differences
The melting curves for BCR-ABL and ABL were identical since they were detected by the same probe (b2-17). Taking Mg 2+ , oligonucleotide concentrations and the sequence for perfect match and mismatch into account a difference in the melting temperature between wild type and polymorphic allele of ⌬ = 3.9 K was calculated according to Schü tz and von Ahsen. 19 
Cell lines
Seven hematopoetic cell lines were investigated for polymorphic (T or C) BCR or BCR-ABL alleles. For the five BCR-ABL positive cell lines (BV173, KYO1, KCL22 -b2a2 BCR-ABL ; K562, LAMA84 -b3a2
BCR-ABL ) all five BCR-ABL alleles and four of five of the normal BCR alleles were of T type. The only C type allele was the BCR allele of LAMA84. Two BCR-ABL negative cell lines (HL60 and KG1a) showed heterozygous configuration of the BCR alleles. In total, 3/9 BCR alleles and 0/5 BCR-ABL alleles were of C type.
Samples of BCR-ABL positive patients and BCR-ABL negative individuals
Ninety-three b2a2 and 80 b3a2 BCR-ABL positive CML patients were analyzed. Forty-eight of 173 BCR-ABL alleles (27.7%), 47/173 BCR alleles (27.2%), and 95 out of a total of 346 BCR or BCR-ABL alleles (27.5%) had the C variant (Table 1) .
Fifty-six BCR-ABL negative individuals were screened. Twenty-two individuals were homozygous for the T allele, 31 were heterozygous, and three were homozygous for the C allele. Overall, 37/112 BCR alleles had the C variant (33.0%) ( Table 1) .
In all individuals investigated, the frequency of the C allele in BCR or BCR-ABL was 132/458 = 28.8% (Table 1 ). The odds ratio for the frequency of polymorphic alleles in patients' populations revealed a lower rate of the C allele in b3a2 BCR-ABL positive patients as compared to BCR-ABL negative individuals (OR = 1.84, P = 0.03, Table 2 ).
The overall frequency of the C or T alleles was 132/458 (p) and 326/458 (q), respectively. 
Sequencing
Sequencing of six BCR, six b2a2 BCR-ABL, and six b3a2 BCR-ABL amplification products revealed the predicted sequence (T vs C) in all cases.
Impact on BCR-ABL quantification by real-time PCR
BCR-ABL transcripts were quantified in two cohorts of b2a2 BCR-ABL positive samples with the T allele (n = 10) and with the C allele (n = 10) using b2-17 and b3-32 probes and by the standard method using a pair of probes mapping to ABL exon 3. The median ratio between the result of b2/b3 hybridization and a3/a3 hybridization was 0.43 (range 0.30-0.51) in the T allele cohort and 0.21 (range 0.07-0.51) in the C allele cohort, respectively (Mann-Whitney test, P = 0.029).
Discussion
Traditional methods for the detection of polymorphisms rely on conventional PCR amplification and subsequent detection of restriction fragment polymorphisms. These approaches are labor-intensive and depend on an appropriate restriction site and complete restriction digestion, which cannot always be achieved. To overcome these problems, we developed a simple and rapid assay using the LightCycler technology.
The LightCycler technology has been employed for several applications to detect hereditary single nucleotide mutations on DNA level in patients suffering from hemochromatosis, 20, 21 Frequent polymorphism in BCR exon b2 A Hochhaus et al 2009 Table 1 Analysis of BCR polymorphism in peripheral blood samples from BCR-ABL positive and negative individuals Individuals Alleles Polymorphism BCR-ABL alleles C BCR alleles C C alleles total n n T/T BCR-ABL BCR-ABL C/C n % n % n % C/BCR T T/BCR C ), methylentetrahydrofolate reductase, 24, 25 and inherited metabolic disorders. 26 Here, we sought to establish a simple RT-PCR-based method to detect a BCR polymorphism that is also present in BCR-ABL. The unambiguous genotyping of polymorphic alleles has been performed by employing combinations of three primers and three hybridization probes.
With a frequency of the C allele of 29.7% in a Caucasian population, this polymorphism should be taken into account when choosing PCR primers, probes for real time PCR and antisense oligonucleotides. For quantitative PCR analysis, for example, probes spanning the b2/a2 fusion region might result in an underestimation of the number of BCR-ABL transcripts. Indeed, Branford et al 13 found that the apparent level of BCR-ABL copies as determined by a TaqMan assay was one order of magnitude lower in cases with the C allele in BCR-ABL. We confirmed the underestimation of BCR-ABL transcripts in C allele patients by comparing two real time PCR approaches: (1) using a pair of hybridization probes spanning the polymorphism and (2) mapping to ABL exon 3, respectively. Method (1) resulted in significant lower transcript numbers in C allele samples. Therefore, probes spanning this region should be avoided. 12, 27 In the past decade, antisense oligonucleotides 15, 28, 29 and
Leukemia ribozymes 30 have received attention for inhibiting BCR-ABL expression and colony formation derived from both human primary CML cells and BCR-ABL positive cell lines. The DNA-RNA heteroduplex formed by hybridization with antisense DNA is the substrate of ribonuclease H. However, sequence specificity is crucial for hybridization efficiency.
14 Therefore, antisense molecules spanning the b2/a2 fusion region and the polymorphic site 28, 31, 32 might be of limited value in a significant proportion of patients. All b2a2 BCR-ABL cell lines that have been treated with antisense or ribozyme reagents have had the T allele in BCR-ABL and thus the influence of the polymorphism in this context is unknown. 33 Investigating a higher number of individuals, we found a lower frequency of C alleles as compared to de V Meissner 8 (28.8% vs 43.5%). The significance of the lower proportion of C BCR-ABL alleles in b3a2 BCR-ABL positive CML patients as compared to the frequency of C BCR alleles in BCR-ABL negative individuals (Fisher's exact test P = 0.03) and of less C BCR-ABL alleles in b3a2 BCR-ABL vs b2a2 BCR-ABL alleles (Fisher's exact test P = 0.04) is unclear.
We conclude that a considerable proportion of BCR and BCR-ABL alleles harbor a C/T replacement in BCR exon b2 of unknown biological significance. However, the base exchange may compromise quantitative PCR approaches or therapeutic strategies using specific antisense oligonucleotides. This polymorphism can easily be detected by a novel real time RT-PCR assay using specific fluorescent hybridization probes and should be taken into account when designing primers, probes or antisense oligonucleotides to BCR or BCR-ABL.
